Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Brain-derived neurotrophic factor (BDNF) activates the receptor tropomyosin-related kinase B (TrkB) with high potency and specificity, promoting neuronal survival, differentiation, and synaptic function. Correlations between altered BDNF expression and/or function and mechanism(s) underlying numerous neurodegenerative conditions, including Alzheimer disease and traumatic brain injury, suggest that TrkB agonists might have therapeutic potential. Using in silico screening with a BDNF loop-domain pharmacophore, followed by low-throughput in vitro screening in mouse fetal hippocampal neurons, we have efficiently identified small molecules with nanomolar neurotrophic activity specific to TrkB versus other Trk family members. Neurotrophic activity was dependent on TrkB and its downstream targets, although compound-induced signaling activation kinetics differed from those triggered by BDNF. A selected prototype compound demonstrated binding specificity to the extracellular domain of TrkB. In in vitro models of neurodegenerative disease, it prevented neuronal degeneration with efficacy equal to that of BDNF, and when administered in vivo, it caused hippocampal and striatal TrkB activation in mice and improved motor learning after traumatic brain injury in rats. These studies demonstrate the utility of loop modeling in drug discovery and reveal what we believe to be the first reported small molecules derived from a targeted BDNF domain that specifically activate TrkB.We propose that these compounds constitute a novel group of tools for the study of TrkB signaling and may provide leads for developing new therapeutic agents for neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LM22A-4 was designed to mimic the loop II domain of BDNF and proven to be a partial agonist.”
From Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression (2018) · cites this paper as Massa et al. 2010
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In vitro work showed that LM22A-4 has neuroprotective properties (Massa et al. 2010).”
From Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression (2018) · cites this paper as Massa et al. 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889
Trk Receptors: Roles in Neuronal Signal Transduction
Huang, E. J., & Reichardt, L. F. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161629 · Cited by 2,537
Neurotrophins and their receptors: A convergence point for many signalling pathways
Chao, M. V. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1078 · Cited by 2,298
Neurotrophin signal transduction in the nervous system
Kaplan, D. R., & Miller, F. D. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00092-1 · Cited by 1,944
Virtual screening of chemical libraries
Shoichet, B. K. (2004) · Nature · doi:10.1038/nature03197 · Cited by 1,425
Ageing and neuronal vulnerability
Mattson, M. P., & Magnus, T. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1886 · Cited by 957
Sairanen, M., Lucas, G., Ernfors, P., Castrén, M., & Castrén, E. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3741-04.2005 · Cited by 763
TrkB Regulates Hippocampal Neurogenesis and Governs Sensitivity to Antidepressive Treatment
Li, Y., Luikart, B. W., Birnbaum, S., Chen, J., Kwon, C.-H., Kernie, S. G., Bassel-Duby, R., & Parada, L. F. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.023 · Cited by 634
Poduslo, J. F., & Curran, G. L. (1996) · Molecular Brain Research · doi:10.1016/0169-328x(95)00250-v · Cited by 614
Research works printed but not linked: 1
- Conte, 2008, Restor Neurol Neurosci., 26, 45
Cited by
Items 301–400 of 403
Гудашева, Т. А., Логвинов, И. О., Povarnina, P. Y., Антипова, Т. А., & Середенин, С. Б. (2015) · Doklady Biochemistry and Biophysics · doi:10.1134/s1607672915010068 · Cited by 6
Kim, T.-W., Ko, Y. J., Youn, K.-H., Hwang, B.-G., Bang, H.-S., & Lee, S. (2021) · Journal of Exercise Rehabilitation · doi:10.12965/jer.2142196.098 · Cited by 6
“is regulated in an activity-dependent manner (Massa et al., 2010).”
BackgroundInfluentialEibl, J. K., Abdallah, Z., Kennedy, A. E., Scott, J. A., & Ross, G. M. (2013) · Neuroscience & Medicine · doi:10.4236/nm.2013.44043 · Cited by 6
Волкова, А. А., Povarnina, P. Y., Никифоров, Д. М., Гудашева, Т. А., & Середенин, С. Б. (2022) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-022-02656-5 · Cited by 6
Neuroprotective Strategies for Alzheimer’s Disease Prevention and Therapy
Simmons, D. A., Yang, T., Massa, S. M., & Longo, F. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00016-2 · Cited by 6
Self-citationBiasing Receptor Tyrosine Kinase Signaling Pathways
Watson, J., Arey, B. J., & Alt, A. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411460-9.00005-7 · Cited by 9
Amyloid-Beta, BDNF, and the Mechanism of Neurodegeneration in Alzheimer’s Disease
Rosa, E., & Fahnestock, M. L. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_43 · Cited by 7
Lee, J. H., Lee, K. H., Ryu, J. H., Kim, M. J., Kim, E., Lee, S., Han, S.-C., Choi, B. T., Shin, Y., & Shin, H. K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117863 · Cited by 5
Gunasekaran, S., Moffat, J. J., Epstein, J. D., Phamluong, K., Ehinger, Y., & Ron, D. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02274-1 · Cited by 5
“4 BDNF in vlOFC-to-DLS circuit moderates habitual alcohol seeking. a Experimental timeline: mice underwent 7 weeks of IA20%2BC alcohol in their home cage (Supplementary Table 1).”
Chanana, V., Zafer, D., Kintner, D. B., Chandrashekhar, J. H., Eickhoff, J. C., Ferrazzano, P. A., Levine, J. E., & Cengiz, P. (2024) · Biology of Sex Differences · doi:10.1186/s13293-024-00596-1 · Cited by 5
Synthesis of BDNF-mimetic dimeric dipeptide GSB-106, a potential neuroprotector drug
Тарасюк, А. В., Помогайбо, С. В., Kurilov, D. V., & Гудашева, Т. А. (2013) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-013-0888-3 · Cited by 5
Amyloid β-Peptide Neurotoxicity Assay Using Cultured Rat Cortical Neurons
Facci, L., & Skaper, S. D. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-536-7_6 · Cited by 5
Kennedy, B. N., Perpetuini, A. C., & Mathoux, J. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.243711 · Cited by 5
“In 2010, LM22A-4 was the first small molecule identified to mimic the TrkB-interacting domain of BDNF, and displayed neuronal-protec-tive effects in several in vitro models (Massa et al., 2010).”
BackgroundSingh, T., Robles, D. A., & Vázquez, M. (2020) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.3025 · Cited by 5
“…clinical trials in the brain as well as through bioengineered materials that embed microspheres of BDNF (Bertram, Rauch, Chang, & Lavik, 2010; Lampe, Kern, Mahoney, & Bjugstad, 2011) and BDNF–TrkB agonists/modulators (Jang et al., 2010; Massa et al., 2010) to increase local BDNF bioavailability.”
BackgroundRoberts, T. P. L., Gandal, M. J., Siegel, S. J., Rodrigues, P. V., & Welsh, J. P. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511980053.017 · Cited by 5
Bidirectional Relationship between the BDNF Gene and miRNA: Implications for PD Pathogenesis
Elangovan, A., Iyer, M., HariKrishnaReddy, D., Wander, A., Kinoshita, M., Krishnan, J., & Vellingiri, B. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00173 · Cited by 4
Emerging role of gene therapy in stroke recovery
Aderinto, N., Abraham, I. C., Ukoaka, B. M., Moradeyo, A. A., Udam, N. G., Aboje, J. E., Oluwakorede, A. T., Adejumo, F. A., Ojapah, E., Babalola, A. E., et al. (2025) · Brain Network Disorders · doi:10.1016/j.bnd.2025.03.002 · Cited by 4
Cancer Biology and the Principles of Targeted Cancer Drug Discovery
Hillmann, P., Schmitz, D., Mestan, J., D'Allonzo, S., & Fabbro, D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12390-x · Cited by 5
Toward Imaging Tropomyosin Receptor Kinase (Trk) with Positron Emission Tomography
Schirrmacher, R., Bernard‐Gauthier, V., Jaworski, C., Wängler, C., Wängler, B., & Bailey, J. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-53176-8_31 · Cited by 4
High throughput assay for compounds that boost BDNF expression in neurons
Liao, G., Xu, H., Shumate, J., Scampavia, L. D., Spicer, T., & Xu, B. (2023) · SLAS DISCOVERY · doi:10.1016/j.slasd.2023.02.005 · Cited by 4
The Causative and Curative Roles of Brain-Derived Neurotrophic Factor in Parkinson’s Disease
Hernández-Baltazar, D., Nadella, R., Llanderal, T. C., Puga-Olguín, A., Barrientos-Bonilla, A. A., Zavala-Flores, L. M., Villanueva-Olivo, A., Sánchez-García, A. D. C., Rovirosa-Hernández, M. D. J., & Rembao-Bojórquez, J. D. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.81215 · Cited by 5
Epigenetic regulation of BDNF-TrkB signaling in the pathophysiology and treatment of mood disorders
Boulle, F. (2013) · Research Publications (Maastricht University) · doi:10.26481/dis.20131129fb · Cited by 8
MeCP2 prevents against sustained ketamine-induced synaptic depression at inhibitory synapses
Piazza, M. K., Weit, A. R., Kavalali, E. T., Neul, J. L., & Monteggia, L. M. (2025) · iScience · doi:10.1016/j.isci.2025.112485 · Cited by 3
“16,22 syndrome ( RTT In this study, we investigated the role of MeCP2 in ketamine’s molecular action at both excitatory and inhibitory synapses utilizing extracellular field recordings, a technique which allows for examination of synaptic changes over hours after ketamine administration,…”
InfluentialKim, T., Park, H., Nam, M.-H., Lee, I.-H., Chen, Z.-Y., Yun, H.-D., & Seo, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13082031 · Cited by 3
“Activation of AKT suppresses pro-apoptotic signaling and inhibits GSK-3 β by phosphorylation at Ser9 [14–16].”
BDNF/TrkB Signaling and Epileptogenesis
Harward, S. C., Huang, Y. Z., & McNamara, J. O. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780197549469.003.0032 · Cited by 3
Lee, J. J., Sitjar, P. H. S., Ang, E., & Goh, J. (2025) · Translational Exercise Biomedicine · doi:10.1515/teb-2024-0038 · Cited by 4
“However, while this mutation may partially account for the variability, its role remains inconclusive, as other pathways likely contribute to exercise-induced neuroprotection [108 – 110].”
7,8-dihydroxyflavone enhances long-term spatial memory and alters brain volume in wildtype mice
Rawlings-Mortimer, F., Lazari, A., Tisca, C., Tachrount, M., Martins-Bach, A. B., Miller, K. L., Lerch, J. P., & Johansen‐Berg, H. (2023) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2023.1134594 · Cited by 3
“Several low molecular weight compounds have been developed and proposed to be tyrosine kinase B (TrkB) receptor agonists that can mimic brain derived neurotrophic factor (BDNF; Jang et al., 2010; Massa et al., 2010).”
BackgroundRescue of Long-Term Spatial Memory by 7,8-Dihydroxyflavone in Mice with Reduced Oligodendrogenesis
Rawlings-Mortimer, F., & Johansen‐Berg, H. (2023) · eNeuro · doi:10.1523/eneuro.0498-22.2023 · Cited by 3
“7,8-DHF is thought to mimic the action of BDNF (Jang et al., 2010; Massa et al., 2010).”
BackgroundInfluentialАнтипова, Т. А., Логвинов, И. О., Deyev, I. E., Povarnina, P. Y., Vakhitova, Y. V., Гудашева, Т. А., & Середенин, С. Б. (2023) · Doklady Biochemistry and Biophysics · doi:10.1134/s1607672923700230 · Cited by 3
“In view of above, since the early 1990s, pharmacologically suitable low-molecular-weight BDNF mimetics have been searched for [8–12].”
BackgroundLin, H., Sasaki, K., Ferdousi, F., Kondo, S., & Isoda, H. (2025) · GeroScience · doi:10.1007/s11357-025-01783-7 · Cited by 4
“BDNF has demonstrated neuroprotective efficacy by activating TrkB in both the hippocampus and striatum of mice, while also improving motor learning capacity in rats following traumatic brain injury [58].”
Huntington’s Disease: Molecular Pathogenesis and New Therapeutic Perspectives
Perandones, C., & Muñoz-Sanjuán, I. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6455-5_6 · Cited by 3
“Although there have been several reports of small-molecule “mimetics” of BDNF and cyclic peptides presumed to activate TrkB receptors, we have not been able to reproduce any of these fi ndings utilizing a comprehensive set of cellular assays, including TrkB dimerization, phosphorylation, and signaling via ERK and pI3K…”
BackgroundTherapeutics of Alzheimer’s Disease
Herrera-Rivero, M., & Emiliano, G. (2011) · InTech eBooks · doi:10.5772/27990 · Cited by 3
Chihara, Y., Iwasaki, S., Kondo, K., & Yamasoba, T. (2011) · Brain Research · doi:10.1016/j.brainres.2011.06.058 · Cited by 4
“Furthermore, several BDNF mimetics, such as deoxygedunin, 7,8- dihydroxyflavone and other small molecular agents, which have been found in animal studies, offer additional treatment opportunities (Jang et al., 2010a,b,c;Massa et al., 2010).”
BackgroundTreatment of anterior ischemic optic neuropathy: Clues from the bench
Liao, Y. J., & Hwang, J. J. (2013) · Taiwan Journal of Ophthalmology · doi:10.1016/j.tjo.2013.09.003 · Cited by 4
Stimulating Neurotrophin Receptors in the Treatment of Neurodegenerative Disorders
Nordvall, G., & Forsell, P. K. A. L. (2014) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-800167-7.00005-5 · Cited by 3
Гудашева, Т. А., Тарасюк, А. В., Sazonova, N. M., Povarnina, P. Y., Антипова, Т. А., & Середенин, С. Б. (2017) · Доклады Академии наук · doi:10.7868/s0869565217250235 · Cited by 3
Long-term functional rescue of trauma-induced vision loss by a novel, small molecule TrkB modulator
Modgil, S., Walker, C. J., Chrenek, M. A., Grossniklaus, H. E., McDonald, F. E., & Iuvone, P. M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0320231 · Cited by 2
“In this direction, synthetic peptide mimetics of BDNF, including essential sequences for TrkB interaction stimulated TrkB [14] but were susceptible to proteolytic degradation.”
Vink, H. A., Ramekers, D., Foster, A. C., & Versnel, H. (2023) · Hearing Research · doi:10.1016/j.heares.2023.108895 · Cited by 2
Nguyen, D. D., Mansur, S., Ciesla, L. M., Gray, N. E., Zhao, S., & Bao, Y. (2024) · Molecules · doi:10.3390/molecules29173992 · Cited by 2
Тарасюк, А. В., Гудашева, Т. А., Sazonova, N. M., Антипов, П. И., Kurilov, D. V., Povarnina, P. Y., Логвинов, И. О., Антипова, Т. А., & Середенин, С. Б. (2014) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162014020137 · Cited by 2
Neurotrophic Factors and Ethanol Neurotoxicity
Davis, M. I. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_47 · Cited by 2
Perspectives on neuroreparative therapies for treating multiple sclerosis
Xiao, J. (2015) · Neural Regeneration Research · doi:10.4103/1673-5374.169610 · Cited by 2
“LM22A4 and Dihydroxyflavone are two non-peptide small molecule TrkB agonists that have been studied in a number of distinct neurological disease models (Massa et al., 2010; Simmons et al., 2013; Zeng et al., 2013), For example, LM22A4 reduces motor impairment and neuropathology in mouse models of Huntington’s disease…”
BackgroundKafshdouziamin, M., Poorebrahim, M., Rahimi, H., Karimipoor, M., & Gheibi, N. (2016) · International Journal of Bioinformatics Research and Applications · doi:10.1504/ijbra.2016.080720 · Cited by 2
Kazana, W., & Zabłocka, A. (2020) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/01.3001.0014.5678 · Cited by 3
Treatment Strategies to Promote Regeneration in Experimental Spinal Cord Injury Models
Hassan, A. U., Nasir, N., & Muzammil, K. (2021) · Neurochemical Journal · doi:10.1134/s1819712421010049 · Cited by 3
BDNF-TrkB Signaling in Lifelong Central Nervous System Myelination and Myelin Repair
Nicholson, M., Yoo, S., Craig, G. A., Murray, S. S., & Fletcher, J. L. (2021) · Springer eBooks · doi:10.1007/978-3-030-71519-9_219-1 · Cited by 2
Effect of Musk on Neurons in the Pattern of Ischemic Stroke
Gochoo, R., Namsrai, O., Begzsuren, D., Jargalsaikhan, B.-E., Lkhagvasuren, E., & Chimedtseren, C. (2020) · Central Asian Journal of Medical Sciences · doi:10.24079/cajms.2020.06.003 · Cited by 2
Антипова, Т. А., Логвинов, И. О., Deyev, I. E., Povarnina, P. Y., Vakhitova, Y. V., Гудашева, Т. А., & Середенин, С. Б. (2023) · Доклады Российской академии наук Науки о жизни · doi:10.31857/s2686738923600218 · Cited by 2
Levy, M. J. F. (2017) · theses.fr (ABES) · doi:10.70675/be792343za725z4b2czb8c5z8a26a8113d23 · Cited by 3
Tutorial on Drug Development for Central Nervous System
Yoon, H.-J., & Kim, J.-S. (2010) · Interdisciplinary Bio Central · doi:10.4051/ibc.2010.2.4.0009 · Cited by 1
Neuroprotective natural products: Promising candidates against neurodegenerative diseases
Dutta, S., & Delpiano, M. A. (2020) · Boletin Latinoamericano y del Caribe de plantas Medicinales y Aromaticas · doi:10.37360/blacpma.20.19.5.31 · Cited by 1
“Massa et al. (2010), also applied these natural products mimicking BDNF in mouse models infected with different neurodegenerative diseases (AD, PD, HD) and found that they were able to prevent cellular death similar as BDNF. Schmid et al. (2012), also reported that natural products mimicking BDNF…”
BackgroundAntonijevic, M., Santos, J. S. O., Dallemagne, P., & Rochais, C. (2024) · Molecular Informatics · doi:10.1002/minf.202400043 · Cited by 1
Airavaara, M., & Saarma, M. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90120-8.00008-3 · Cited by 1
Unleashing the Potential of Cubosomes to Overcome Ocular Barriers in Precision Drug Delivery
Narula, H., Devi, N., Singh, T. G., Kumar, P., Dhiman, S., & Dora, C. P. (2025) · Advanced Therapeutics · doi:10.1002/adtp.202500267 · Cited by 1
Alqasem, A. A., Binshaya, A. S., & Abalkhail, A. (2026) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-026-10283-0 · Cited by 1
Neuroprotection in Demyelinating Diseases: The Therapeutic Potential of the Neurotrophins
Xiao, J., Hughes, R. A., & Murray, S. S. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_36 · Cited by 1
Szabla, K. L., & Monteggia, L. M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-410529-4.00016-4 · Cited by 1
Brain-Derived Neurotrophic Factor and Its Role in Stress-Related Disorders
Notaras, M. J., & van den Buuse, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813156-5.00023-6 · Cited by 2
BDNF-TrkB Signaling in Lifelong Central Nervous System Myelination and Myelin Repair
Nicholson, M., Yoo, S., Craig, G. A., Murray, S. S., & Fletcher, J. L. (2022) · Springer eBooks · doi:10.1007/978-3-031-15080-7_219 · Cited by 1
Selective, Intrinsically Fluorescent Trk Modulating Probes
Pewklang, T., Thompson, T., Sefiani, A., Geoffroy, C. G., Kamkaew, A., & Burgess, K. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00290 · Cited by 2
Shi, J., Yang, T., Li, Y., Zhong, L., Longo, F. M., & Massa, S. M. (2025) · Neurotrauma Reports · doi:10.1089/neur.2024.0117 · Cited by 1
“21 In a mouse model of stroke, LM22A-4 was found to promote striatal TrkB phosphorylation, increase sub-ventricular zone and peri-infarct neurogenesis, and improve gait, even when administered 72 h after injury.”
Self-citationMMP-2 Sensitive Self-assembled Peptide Nanoscaffolds for Neural Tissue Engineering
Koss, K. R. (2016) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r38c9rm0q · Cited by 1
Kenneth, E. N., Mahapatra, S., & Hrishikesh, M. (2011) · InTech eBooks · doi:10.5772/21042 · Cited by 1
“BDNF mimetics have made progress toward a useful therapeutic reagent with efficacy studies in rodents (Massa et al., 2010).”
Khalin, I., Musina, N. Z., Alyautdin, R. N., Романов, Б. К., & Bunatyan, N. D. (2015) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-015-1175-2
Pereira, V. S. (2011) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2011.tde-11082011-132630
New Small Molecule Drug Discovery for Alzheimer's Disease
Liu, K., Zhang, M., & Nagappan, G. (2012) · Frontiers in neuroscience · doi:10.1201/b11986-6
Investigating the Efficacy of Novel TrkB Agonists to Augment Stroke Recovery
Warraich, Z. (2013) · PhDT
Pereira, V. S. (2015) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2015.tde-07072015-084140
Effect of Korean Music Therapy on Depression: Daegeum Playing of Arirang
Kim, H., Kim, N., Ko, K.-J., Jeong, H., & Kim, H. (2017)
Carrillo-Jiménez, A. (2018) · Deposito de Investigacion Universidad de Sevilla (University of Seville)
A review on brain-derived neurotrophic factor and its role in depression and anxiety
Iacob, V., Palimariciuc, M., Chiriță, V., & Chiriță, R. (2020) · Bulletin of Integrative Psychiatry · doi:10.36219/bpi.2020.3.09
“safe and regulatable growth factor expression in the CNS (58); and by developing peptide mimetics of growth factors with specificity for degenerating cell systems (59).”
BackgroundTargets, Tracers and Translation – Novel Radiopharmaceuticals Boost Nuclear Medicine
Reischl, G. (2019) · MDPI eBooks · doi:10.3390/books978-3-03921-314-6
Fletcher, J. L., Wood, R. J., Prawdiuk, A. R., O’Rafferty, R., Ehrlich, O., Gonsalvez, D. G., & Murray, S. S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.19.440405
“These results are 135 inconsistent with previous findings, wherein recombinant BDNF, and other compounds, TDP6 and LM22A136 4, shown to activate TrkB signalling in the cuprizone model, and in multiple in vitro contexts [12,14,21,22], 137 did promote remyelination by increasing the proportion of myelinated axons and/or…”
MethodResultThe role of neurotrophic factors in Alzheimers disease
Kemppainen, S. (2018) · UEF eRepo (University of Eastern Finland) · Cited by 1
TrkB Activators for the Treatment of Traumatic Vision Loss
Iuvone, P. M., & Diamond, B. (2013) · Defense Technical Information Center (DTIC) · doi:10.21236/ada606287
Francisco llama a anunciar con alegría el evangelio
Ballester, M. G. (2013) · Teología Espiritual
29th Annual GP2A Medicinal Chemistry Conference
Hélesbeux, J., Carro, L., McCarthy, F. O., Moreira, V. M., Giuntini, F., O’Boyle, N. M., Matthews, S. E., Bayraktar, G., Bertrand, S., Rochais, C., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14121278
“Because of that, and based on the main structural characteristics Pharmaceuticals 2021, 14, 1278 9 of 53 of LM22A-4 [43], a known activator of the TrkB receptor, and RS67333 [44], a partial 5-HT4 receptor agonist, we have designed and synthesized a small set of compounds with potential dual activities, in order to not…”
InfluentialRenthal, W. R., Szabla, K. L., & Monteggia, L. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813955-4.00021-0
Ng, Z. M. W. (2022) · Journal of Student Research · doi:10.47611/jsrhs.v11i4.3352
Javed, S., Chang, Y.-T., Cho, Y., Lee, Y., Chang, H., Haque, M., Lin, Y. C., & Huang, W. (2023) · eLife · doi:10.7554/elife.90333.1
Molecular mechanisms of synapse formation in neurodegenerative diseases: a treatment approach
(2023) · International Research Journal of Modernization in Engineering Technology and Science · doi:10.56726/irjmets47447
Novel therapeutics for diverse neurodegenerative disorders
Chaurasia, R. N., & Favas, T. T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95735-9.00051-6 · Cited by 1
Prophylaxis of Epileptogenesis in Injury and Genetic Epilepsy Models
Prince, D. A., & Gu, F. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780197549469.003.0068
Piazza, M. K., Renthal, W. R., & Monteggia, L. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19041-4.00005-4
Neurotrophin Peptidomimetics: A new era in precision neurology and drug development
Pal, S. S., Kumar, V., ., S., ., S., Bani, K. S., & Gupta, N. (2025) · International Journal of Pharmaceutical Research and Development · doi:10.33545/26646862.2025.v7.i1f.138
Brain-derived neurotrophic factor as a target for the search of anti-addiction drugs
Khalimanov, M. S., Grigorevskikh, E., Zavadich, K. A., Sologov, S. I., Traschenkova, D. A., Александровна, Т. К., Polikarpov, E., Sologova, S. S., Kudlay, D. A., & Smolyarchuk, Е. А. (2025) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2025-13-1-4-19
Application of synthetic biology in age-related and neurodegenerative disease
Ghosh, S., Kundu, S., Jana, R., Basu, B., & Prajapati, B. G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33649-2.00011-3
Yang, T., Liu, H., Tran, K. C., Leng, A., Massa, S. M., & Longo, F. M. (2020) · Figshare · doi:10.6084/m9.figshare.12923390
Self-citationYang, T., Liu, H., Tran, K. C., Leng, A., Massa, S. M., & Longo, F. M. (2020) · Figshare · doi:10.6084/m9.figshare.12923387
Self-citationYang, T., Liu, H., Tran, K. C., Leng, A., Massa, S. M., & Longo, F. M. (2020) · Figshare · doi:10.6084/m9.figshare.12923381
Self-citationYang, T., Liu, H., Tran, K. C., Leng, A., Massa, S. M., & Longo, F. M. (2020) · Figshare · doi:10.6084/m9.figshare.12923384
Self-citationYang, T., Liu, H., Tran, K. C., Leng, A., Massa, S. M., & Longo, F. M. (2020) · Figshare · doi:10.6084/m9.figshare.12923378
Self-citationDestro, M. (2023) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
García-Rodríguez, R., de la Fuente, S. G., Guerrero‐Valero, M., Carús-Cadavieco, M., Clares, I., Cabañas, C., Palomer, E., Guix, F. X., & Dotti, C. G. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.18.706575
Mustafa, F., Kanwal, W., Umar, R. A. B., Zeeshan, M., Baig, A. A., & Taib, W. R. W. (2026) · Life Sciences Medicine and Biomedicine · doi:10.28916/lsmb.10.1.2026.209
“…mutant BDNF-TrkB complex, is lower (-1211 kcal/mol, i.e., less negative) than the docking score for the wild-type complex (-1217.5 kcal/mol), in line with the study conducted by Massa et al., this suggests that BDNF mutation can reduce binding affinity between BDNF and TrKB (Massa et al., 2010).”
InfluentialEpigenetic regulation of BDNF-TRKB signaling in the pathophysiology and treatment of mood disorders
Boulle, F. (2013) · theses.fr (ABES) · doi:10.70675/7796cc83z9f91z48c6zadb1zb6a90897b5d5
A De Novo Peptide That Induces Axonal Growth Through TrkB Activation
Maini, R., Tamada, K., Fukuda, K., Takumi, T., & Suga, H. (2026) · ChemBioChem · doi:10.1002/cbic.70517
Patil, S. P., Kuehn, B. R., Schlosser, R., & Samohod, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.10.750759
“To overcome these lim-50 itations, significant efforts have been directed toward the development of small-molecule neurotrophin mimetics capable of selectively activating Trk receptors [12–14].”
Yang, T., Tran, K. C., Leng, A., Langness, V. F., Massa, S. M., & Longo, F. M. (2026) · Cells · doi:10.3390/cells15191822
Self-citation
Metadata
- Authors
- Massa, S. M., Yang, T., Xie, Y., Shi, J., Bilgen, M., Joyce, J. N., Nehama, D., Rajadas, J., & Longo, F. M.
- Affiliations
- University of California, San Francisco (US)
- Stanford University (US)
- University of North Carolina at Chapel Hill (US)
- Medical University of South Carolina (US)
- Banner Sun Health Research Institute (US)
- Corresponding author
- Longo, Frank M.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2010-05-03
- Volume
- 120
- Issue
- 5
- Pages
- 1774-1785
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2860903
- OpenAlex
- W2055583081
- Cited by
- 406
- References
- 64
- Citations by year
- 2026: 6 · 2025: 22 · 2024: 18 · 2023: 25 · 2022: 22 · 2021: 21 · 2020: 42 · 2019: 22 · 2018: 18 · 2017: 26 · 2016: 23 · 2015: 21 · 2014: 40 · 2013: 41 · 2012: 32
- FWCI
- 12.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- U.S. Department of Defense (DAMD170310532)
- U.S. Department of Veterans Affairs
- Alzheimer's Association
- Koret Foundation
- Jean Perkins Foundation
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Keywords
- BDNF mimetic, TrkB signaling, brain-derived neurotrophic factor, small molecule agonists, neurotrophic activity, neurodegeneration, traumatic brain injury, Alzheimer's disease, pharmacophore modeling, loop domains, hippocampal neurons, motor learning, neurodegenerative disease therapeutics
- MeSH terms
- Animals, Hippocampus, Kinetics, Male, Mice, Inbred C57BL, Models, Biological, Neurons, Phosphorylation, Protein Binding, Signal Transduction, Rats, Sprague-Dawley, Brain-Derived Neurotrophic Factor, Neurodegenerative Diseases, Receptor, trkB, NIH 3T3 Cells, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.